Clinical Trial Update: Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial of AV650 for spasticity in people with multiple sclerosis was terminated; the update discusses safety and preliminary effectiveness data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• AV650

Snippet

Sponsor: Avigen | Conditions: Muscle Spasticity | Phase 2 | Status: TERMINATED